Ozempic is 'only for diabetics': fact-checking a viral TikTok claim

What did @teatherapytips101 actually say?

Here's the awkward truth: the transcript contains song lyrics, not a health explanation. The words "And it started pretty slowly" and "it's falling into pieces" are from a song, not a medical testimony. The caption does the heavy lifting here, claiming you should "NEVER take it if you're not diagnosed with diabetes" and that "the side effects are real." So we're fact-checking the caption, not the spoken content, because there isn't any. That matters. Viewers see the caption and hashtags first, and those are making specific health claims the video's audio never actually supports.

The hashtag #SayNoToOzempic and the framing of a personal regret story suggest this is meant as a cautionary tale about off-label semaglutide use. The creator positions themselves as someone who learned the hard way. Whether that experience is real, we can't verify. What we can verify is whether the underlying claim, that non-diabetics should never take Ozempic, holds up against the clinical record.

Does the science back this up?

No, not cleanly. Semaglutide is FDA-approved for chronic weight management in adults without diabetes under the brand name Wegovy, approved in 2021. The claim that only diabetics should use semaglutide ignores a substantial and growing body of evidence supporting its use in obesity medicine.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) enrolled adults with obesity but without type 2 diabetes and found 2.4 mg weekly semaglutide produced an average 14.9% body weight reduction versus 2.4% with placebo. These were not diabetic patients. The FDA reviewed this data and approved Wegovy specifically for non-diabetic adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition.

More recently, the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) found semaglutide reduced major cardiovascular events by 20% in overweight or obese adults without diabetes. The cardiovascular benefit extends beyond diabetic populations. The science here is not ambiguous: semaglutide has legitimate, studied applications outside diabetes care.

What did they get wrong (or right)?

Wrong on the central claim. "Never take it if you're not diagnosed with diabetes" is a sweeping, inaccurate statement that contradicts FDA approvals and multiple large randomized controlled trials. Wegovy, the 2.4 mg semaglutide formulation, exists precisely because the drug works for non-diabetic obesity. Conflating Ozempic (approved for type 2 diabetes) with semaglutide's full clinical picture is a common but consequential error.

What they may have gotten partially right: Ozempic specifically is not FDA-approved for weight loss in non-diabetic patients. If someone is taking Ozempic off-label for weight loss without a proper clinical evaluation, that is a real concern worth discussing. Access without medical oversight, unclear dosing titration, and ignoring contraindications are genuine risks. The side effect profile, including nausea, vomiting, gastroparesis risk, and rare pancreatitis cases, is also real and documented (Davies et al., 2021, Diabetes Care).

But framing legitimate GLP-1 receptor agonist therapy as something non-diabetics should categorically avoid is not a health warning. It's misinformation with a wellness aesthetic.

What should you actually know?

Semaglutide is not a diabetes-only drug. There are two FDA-approved semaglutide products: Ozempic (0.5 mg to 2 mg, for type 2 diabetes) and Wegovy (2.4 mg, for chronic weight management). Using Ozempic off-label for weight loss in a non-diabetic person is different from using Wegovy as indicated. That distinction matters clinically and legally, but it does not mean non-diabetics should never access semaglutide at all.

Side effects are real and should be taken seriously. Gastrointestinal symptoms affect a significant portion of users. The STEP trials reported nausea in roughly 44% of semaglutide participants versus 16% on placebo. There are also concerns about muscle mass loss during rapid weight reduction (Bikou et al., 2023, Nutrients), which is relevant for anyone using GLP-1 therapy without concurrent resistance training and adequate protein intake.

Anyone considering semaglutide, diabetic or not, should be evaluated by a licensed clinician who can assess their full medical history, contraindications, and appropriate formulation. That is not what this video is communicating.

The bottom line on this video

The transcript is literally a song. The health claims live entirely in the caption, and those claims are misleading. "Never take it if you're not diagnosed with diabetes" ignores FDA approvals, large-scale trials, and the clinical reality that obesity is a disease with its own treatment protocols. The side effect concern is legitimate but poorly framed. This video earns credit for acknowledging that GLP-1 drugs carry real risks. It earns no credit for the categorical "never" it places on non-diabetic use. 12,400 viewers saw this. That's 12,400 people who may now have an inaccurate framework for a drug class that, under proper medical supervision, could meaningfully benefit some of them.